Analysis of Multiplexed Proteins at Single-Cell Level Provides a Deeper Understanding of Cancer
ALISO VIEJO, CA, December 9, 2013 -- GE Healthcare today announced results from two studies that show how using the MultiOmyx™ Hodgkin Lymphoma (HL) Profile and an investigational profile for breast cancer may improve assessment of the two diseases in subsets of patients.
business unit
tags
GE demonstrates the "Power of Partnership" through innovative technologies that improve patient care, comfort and productivity
As the 99th annual meeting of the Radiological Society of North America (#RSNA13) opened today, GE Healthcare, a unit of General Electric Company (NYSE:GE), demonstrated its commitment to delivering innovative healthcare technologies to solve clinicians' most pressing challenges in patient care, comfort and productivity.
business unit
tags
Princeton, NJ -- November 27, 2013 -- GE Healthcare today announced results from a new study, which showed that patients receiving Visipaque™ (iodixanol 320mg I/ml) were less likely to experience discomfort, characterized by heat or cold sensation or pain upon injection, than patients receiving Isovue® (iopamidol 370 mg I/ml). As with other iodinated contrast agents, Visipaque is often associated with sensations of discomfort, heat or pain. The data were published online in Acta Radiologica.[i]
business unit
tags
Princeton, NJ, September 30, 2013 -- GE Healthcare Life Sciences today announced that its Radiopharmacy Services division has earned The Joint Commission's Gold Seal of Approval™ for accreditation by demonstrating compliance with The Joint Commission's national standards for health care quality and safety.[i] GE Healthcare's national network of 31 Radiopharmacies are accredited as part of The Joint Commission's Home Care Accreditation program.